Business Context and Reporting Period
MediciNova, Inc. filed this Form 8-K on November 15, 2010, to disclose a Japanese financial report ("Kessan Tanshin") filed with the Osaka Securities Exchange on November 16, 2010 (Japanese Standard Time). The report covers the quarter ended September 30, 2010, and provides updated full-year guidance for the fiscal year ending December 31, 2010.
Key Financial Metrics
The filing provides full-year 2010 estimates rather than specific quarterly results for the period ended September 30, 2010, noting that the Japanese report is substantially the same as the Form 10-Q except for the following supplemental forecast data:
- Revenues: $0 (No revenue expected for the full year).
- Operating Loss: $(17,919,000).
- Net Loss: $(17,702,000).
- Expected Basic and Diluted Loss Per Share: $1.43 (based on a weighted average of 12,410,519 shares).
- Currency Translation: Supplementary financial statements in Japanese yen were translated at a rate of 83.82 yen per U.S. dollar as of September 30, 2010.
The filing does not provide specific values for cash flow, debt, or liquidity metrics for the current period.
Material Changes and Guidance
Management confirmed that the estimated results for the full year ending December 31, 2010, remain unchanged from the forecast previously provided on March 25, 2010. The company expects to continue operating at a loss with no revenue generation for the fiscal year.
Risks, Contingencies, and Management Commentary
Management cautioned that the estimates are based on assumptions subject to significant risks and uncertainties. Key risk factors include:
- Clinical Development: Uncertainty regarding clinical trial results, regulatory approvals, and potential delays or failures in product development.
- Third-Party Reliance: Risks associated with third parties conducting clinical trials and manufacturing product candidates.
- Capital Resources: The ability to raise sufficient capital to complete product development plans.
- Strategic Integration: Risks related to the integration of the Avigen, Inc. acquisition and the combined ibudilast development programs.
- Internal Controls: The ability to remediate deficiencies in internal controls.
- Market Conditions: Potential impairments to the investment portfolio due to credit and capital market uncertainties.
Independent auditors have not compiled or reviewed these forecasted results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the full-year 2010 loss estimates of approximately $17.7 million against actual results upon year-end.
- Confirm the status of the Avigen, Inc. acquisition integration and the combined ibudilast development program.
- Monitor the company's ability to raise capital given the projected zero revenue and significant operating losses.
- Review subsequent filings for updates on clinical trial progress and regulatory milestones.
- Check for any changes in the weighted average share count used for loss per share calculations.